Antioxidant Properties of Surfactant

Surfactant treatment is one of the milestones of respiratory distress syndrome (RDS) treatment in preterm infants, but it has been also demonstrated to exert consistent antioxidant and anti-inflammatory activities. Exogenous natural surfactant contains antioxidant enzymes, such as catalase (CAT) and superoxide dismutase (SOD), and nonenzymatic antioxidant molecules, such as plasmalogens and polyunsaturated phospholipids (PUPLs). Moreover, surfactant can contribute to the modulation of intra-alveolar inflammatory processes through the regulation effect of the surfactant A (SP-A) and B (SP-B) proteins. Although less extensively investigated, these functions may contribute to the efficacy of exogenous surfactant administration in preterm neonates with RDS.

• Publication year

  2014

• Venue

  Perinatal and Prenatal Disorders

• Publication date

  2014-12-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-4939-1405-0_12PMCID 7121990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic polymorphisms of antioxidant enzymes as risk factors for oxidative stress-associated complications in preterm infants

  2012cited by this paper
• Genetic polymorphisms of antioxidant enzymes in preterm infants

  2012cited by this paper
• aEEG in preterm infants

  2012cited by this paper
• Perinatal inflammation and lung injury.

  2012cited by this paper
• Early identification of the risk for free radical-related diseases in preterm newborns.

  2010cited by this paper
• Oxidative stress and antioxidant strategies in newborns

  2010cited by this paper
• Maturation of the antioxidant system and the effects on preterm birth.

  2010cited by this paper
• Anti‐oxidant enzymes and related elements in term and preterm newborns

  2009cited by this paper
• Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials

  2009cited by this paper
• Oxidative stress in resuscitation and in ventilation of newborns

  2009cited by this paper
• Modification of surfactant protein D by reactive oxygen‐nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo

  2009cited by this paper
• Superoxide dismutase and catalase activity in naturally derived commercial surfactants

  2009cited by this paper
• Polyunsaturated fatty acids as antioxidants.

  2008cited by this paper
• Choosing a Right Surfactant for Respiratory Distress Syndrome Treatment

  2008cited by this paper
• Annual Summary of Vital Statistics: 2006

  2008cited by this paper
• Lung antioxidant enzymes are regulated by development and increased pulmonary blood flow.

  2007cited by this paper
• Dysplasia: A review

  2007cited by this paper
• The Contribution of Preterm Birth to Infant Mortality Rates in the United States

  2006cited by this paper
• Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity.

  2005cited by this paper
• Preterm delivery

  2005cited by this paper
• Surfactant proteins and inflammation: the yin and the yang.

  2004cited by this paper
• Accumulation of Inhibitory κB-α as a Mechanism Contributing to the Anti-Inflammatory Effects of Surfactant Protein–A

  2004cited by this paper
• Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase.

  2003cited by this paper
• Distinct roles for lung collectins in pulmonary host defense.

  2002cited by this paper
• Surfactant proteins a and d and pulmonary host defense.

  2001cited by this paper
• Cell‐specific expression of manganese superoxide dismutase protein in the lungs of patients with respiratory distress syndrome, chronic lung disease, or persistent pulmonary hypertension *

  2001cited by this paper
• Increased levels of nitrate and surfactant protein a nitration in the pulmonary edema fluid of patients with acute lung injury.

  2001cited by this paper
• Lung Surfactant Proteins A and D in Innate Immune Defense

  2000cited by this paper
• Surfactant protein A differentially regulates IFN-gamma- and LPS-induced nitrite production by rat alveolar macrophages.

  2000cited by this paper
• Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants.

  2000cited by this paper
• Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often

  2000cited by this paper
• Plasmalogens reduce the viscosity of a surfactant-like phospholipid monolayer

  1999cited by this paper
• Acute neonatal respiratory distress in Italy: a one‐year prospective study

  1998cited by this paper
• Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages.

  1998cited by this paper
• Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants

  1997cited by this paper
• Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome.

  1997cited by this paper
• Clinical surfactant preparations mediate SOD and catalase uptake by type II cells and lung tissue.

  1996cited by this paper
• The role of inflammation in the pathogenesis of bronchopulmonary dysplasia

  1995cited by this paper
• Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits.

  1995cited by this paper
• Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens.

  1995cited by this paper
• A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome

  1993cited by this paper
• Mitigation of oxidant injury to lung microvasculature by intratracheal instillation of antioxidant enzymes.

  1993cited by this paper
• Mechanisms of peroxynitrite-induced injury to pulmonary surfactants.

  1993cited by this paper
• Characterization of antioxidant activities of pulmonary surfactant mixtures.

  1990cited by this paper
• Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract.

  1990cited by this paper
• Experimental evaluation of surfactants for replacement therapy.

  1988cited by this paper
• A possible role for plasmalogens in protecting animal cells against photosensitized killing.

  1988cited by this paper
• Neutrophil-mediated pulmonary vascular injury. Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung.

  1987cited by this paper
• Prenatal development of lung antioxidant enzymes in four species.

  1987cited by this paper
• Human surfactant treatment of severe respiratory distress syndrome: pulmonary effluent indicators of lung inflammation.

  1986cited by this paper

• Extrusion-Based 3D Printing of Rutin Using Aqueous Polyethylene Oxide Gel Inks

  2025cites this paper
• Protective effects of microbial biosurfactants produced by Bacillus halotolerans and Candida parapsilosis on bleomycin-induced pulmonary fibrosis in mice: Impact of antioxidant, anti-inflammatory and anti-fibrotic properties via TGF-β1/Smad-3 pathway and miRNA-326.

  2024cites this paper
• Using a neonatal rat model to explore the therapeutic potential of coenzyme Q10 in prematurity under hyperoxia

  2022cites this paper
• The Potential Role of Bioactive Plasmalogens in Lung Surfactant

  2021cites this paper
• Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives

  2021cites this paper